07:31 GMT22 October 2020
Listen Live
    Get short URL
    0 0 0

    Besides the United States, South Korea, and Japan remdesivir has been approved for emergency use for serious COVID-19 patients in India. Four Indian drug companies are manufacturing remdesivir in India under a license from Gilead Sciences Inc.

    Swadeshi Jagaran Manch (SJM), an ideological ally of India's ruling nationalist Bharatiya Janata Party (BJP), has urged Prime Minister Narendra Modi to seek a waiver of WTO provisions on intellectual property rights for easy accessibility of drugs and vaccines for COVID-19 in the country.

    In a letter to Modi on Wednesday, SJM's national coordinator Aswhani Mahajan alleged some drug manufacturers have "wrongly obtained patents" in India to control competition, without any substantial reduction of prices. 

    Mahajan cited the case of remdesivir, which is sold on the Indian market at $55 to $74 per vile, while researchers have calculated its cost at less than $1. He charged IP protection as the primary reason for the higher cost in the country.

    "India has been a victim of such greed. Gilead Sciences is using its wrongly obtained patent to control the competition. Though Gilead granted 7 voluntary licenses to Indian generic companies there is no substantial reduction of prices", reads the SJM's letter to the prime minister.

    Indian pharmaceutical company Zydus Cadila launched the least expensive version of remdesivir at $37.4 per 100 mg vial last month.

    The World Trade Organisation (WTO) made a Doha Declaration on TRIPs (Trade Related Intellectual Property Rights) to improve access to medicines in developing and the least developed countries.

    The World Health Organisation (WHO), while reiterating its commitment to the TRIPS agreement said it "can and should be interpreted and implemented in a manner supportive of WTO members' right to protect public health and, in particular, to promote access to medicine for all".

    India and South Africa have sought waivers of patents and the provisions of TRIPS for drugs and vaccines for the prevention, containment, and treatment of COVID-19. If the WTO accepts the proposal, it would facilitate the technology transfer of effective COVID-19 related vaccines, therapeutics, or diagnostic tests.

    It would also ensure the availability, accessibility, and affordability of life-saving drugs and vaccines used for COVID-19 in developing countries like India, without long-winding negotiations, legal hurdles, and delays.

    COVID-19 cases have seen a drastic uptick in India and as per data released by federal Health Ministry on Wednesday the tally crossed 6.7 million, with 104,555 deaths. On the positive side, 85.02 percent of patients have recovered from the virus so far.


    India's 1st Adjuvanted COVID-19 Vaccine COVAXIN to Boost Immune System, Developer Says
    India to Consider Domestic Production of Ebola Treatment Drug Remdesivir as Cure For COVID-19
    Zydus Cadila Launches India's Least Expensive Version of 'Remdesivir' Amid Reported Shortage
    Narendra Modi, Bharatiya Janata party (BJP), COVID-19, New Delhi, India
    Community standardsDiscussion